This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines
Strahlentherapie und Onkologie Open Access 08 December 2022
-
Extrachromosomal circular DNA: biogenesis, structure, functions and diseases
Signal Transduction and Targeted Therapy Open Access 02 October 2022
-
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Signal Transduction and Targeted Therapy Open Access 17 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Gao, X. et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR–STAT3 signalling. Nat. Cell Biol. 23, 278–291 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harjes, U. EGFR is going circular. Nat Rev Cancer 21, 280 (2021). https://doi.org/10.1038/s41568-021-00350-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41568-021-00350-4
This article is cited by
-
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines
Strahlentherapie und Onkologie (2023)
-
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Signal Transduction and Targeted Therapy (2022)
-
Extrachromosomal circular DNA: biogenesis, structure, functions and diseases
Signal Transduction and Targeted Therapy (2022)